CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Successful Treatment in UK Very Resistant Gonorrhea Case

Published: Fri, 20 Apr 2018 16:32:00 EDT
Ertapenem antibiotic treatment has been successful for a man from the UK who acquired a strain of 'very resistant gonorrhea' while on vacation in Southeast Asia.
Medscape Medical News

AGS 2018

Published: Fri, 20 Apr 2018 15:32:24 EDT
Read clinically focused news coverage of key developments from AGS 2018.
Medscape Internal Medicine

Real-World Data Back Coronary Sinus Stent in Refractory Angina

Published: Fri, 20 Apr 2018 14:51:28 EDT
About 80% of patients with chronic, refractory angina appear to respond to the novel stent, but its path to US approval is unsettled.
Medscape Medical News
Displaying results 4-6 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Biogen pays Ionis $1B to form discovery-stage pact

Published: Fri, 20 Apr 2018 12:28:00 +0000
Biogen is paying $1 billion to enter into a discovery-stage R&D pact with Ionis Pharmaceuticals. The deal gives Biogen a chance to pick up a series of neurological antisense drugs identified by Ionis.

FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Published: Fri, 20 Apr 2018 09:18:30 +0000
Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety.

MorphoSys supersizes IPO, bagging $208M for cancer R&D

Published: Fri, 20 Apr 2018 09:06:42 +0000
MorphoSys has supersized its IPO, pulling in $208 million to develop its anti-CD19 antibody MOR208. The dialed-up IPO haul gives MorphoSys a $500 million-plus war chest to crash the CAR-T party with a drug it thinks provides safer, more durable efficacy without the cost or complexity of cell therapies.
Displaying results 4-6 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top